Bio-Thera And BeiGene Partner For Bevacizumab In China
Partnered Territory Includes Hong Kong, Macau and Taiwan
Executive Summary
Bio-Thera is collaborating with BeiGene for BAT1706, a biosimilar to Avastin (bevacizumab), to develop, manufacture and commercialize the product in Greater China.
You may also be interested in...
Bio-Thera Follows EU Bevacizumab Biosimilar Filing With FDA Goal Date
China’s Bio-Thera is continuing its journey to bring biosimilars to patients across the globe, with its BAT1706 biosimilar bevacizumab candidate accepted for filing by the US Food and Drug Administration.
Biomm Backs Bio-Thera’s Brazilian Bevacizumab
China’s Bio-Thera has struck a licensing deal with Biomm that will give the Brazilian company exclusive rights to market the BAT1706 bevacizumab biosimilar in its home market.
Bio-Thera Ventures Outside China With European Bevacizumab Filing
China’s Bio-Thera Solutions has ventured outside of its domestic market for the first time by filing an application for a biosimilar version of Avastin with the European Medicines Agency. The company has also revealed its timeline for a submission to the FDA.